Back to Agendas
PHARMA MEDICAL AFFAIRS: VISION THROUGH 2020
Session Chair(s)
Gustavo Kesselring, MD
Senior Visiting Lecturer
KING´S COLLEGE LONDON, Brazil
Medical affairs organisations have emerged over the past half century in response to federal regulations around the separation of medical and commercial activities within drug companies. Many companies also chose to focus R&D resources on developing new products and moved post-launch activities, such as finding new indications for existing drugs, into the medical affairs function. Continued pressure from regulatory agencies and public sentiment have pushed more and more activities into Medical affairs organisations. Today, these organisations commonly involve the following medical activities: Medical education, medical field teams, post-launch clinical trials, medical-information services, medical communications, medical strategic activities and health economics and outcome research activities. The vision from medical departments of three global pharmaceutical companies will be addressed and balanced with the vision of the Standing Committee of the European Doctors (CPME).
Speaker(s)
Panel Discussion
Michael Devoy
Bayer AG, Germany
Panel Discussion
Jacques de Haller
Standing Committee Of European Doctors, Switzerland
Vice President
Panel Discussion
Michael Rosenblatt, MD
Flagship Pioneering, United States
Chief Medical Officer
Panel Discussion
Tamas Suto
Sanofi, France
Head of Medical Excellence
Have an account?